Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jerome D. Jabbour
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 1.70
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -94.11
Financials
Revenue
$0.00-100.0%Net Income
$-1.33MEBITDA
$-1.78MFree Cash Flow
$-1.84MEPS (diluted)
$-0.21Shares Outstanding (diluted)
6.41M+455.8%Operating Expenses
$1.55MCash & Debt
$761.0KReturn of Capital
$0.00Revenue by Segment (annual)
$125.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-10.35M | $-2.00 |
| 2024 | $0.00 | $-24.25M | $-4.98 |
| 2023 | $1.10M | $-22.94M | $-5.28 |
| 2022 | $3.19M | $-21.00M | $-3.00 |
| 2021 | $33.0K | $-23.28M | $-5.04 |
| 2020 | $158.3K | $-22.45M | $-5.23 |
| 2019 | $89.8K | $-17.37M | $-5.37 |
| 2018 | $119.8K | $-14.08M | $-7.18 |
| 2017 | $149.7K | $-15.49M | $-8.56 |
| 2016 | $0.00 | $-7.60M | $-6.59 |
| 2015 | $194.5K | $-9.14M | $-8.87 |
| 2014 | $0.00 | $-10.22M | $-15.93 |
| 2013 | $0.00 | $-3.71M | $-5.80 |
| 2012 | $0.00 | $-116.1K | $-0.58 |
Valuation
MTNBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+33.33%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform
View source ↗ - Newsglobenewswire.com·9d ago·Negative
… with NYSE American Continued Listing Standards BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a comp…
View source ↗
Earnings
Thu, Nov 12(in 8 weeks)
Consensus estimate $-1.32 per share
Typical surprise +62.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.21 vs $-1.32beat
- Fri, May 8$-0.30 vs $-1.32beat
- Tue, Mar 31$-0.26 vs $-0.78beat
- Mon, Nov 10$-0.40 vs $-1.05beat
- Thu, Aug 14$-1.03 vs $-1.25beat
- Tue, Apr 15$-1.68 vs $-1.50miss
Estimates and results for MTNB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MTNB officers and directors.
- Bought
- $3.7m
- Sold
- —
6 trades
0 trades
- Sanitam Partners Llcbought
- Sanitam Partners Llcbought
- Eide Robert Jbought
- Eide Robert Jbought
- Pembroke & Partners Llcbought
- Pembroke & Partners Llcbought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MTNB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.